Advertisement

Clinical Rheumatology

, Volume 36, Issue 2, pp 469–475 | Cite as

Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis

  • Angela Ceribelli
  • Natasa Isailovic
  • Maria De Santis
  • Elena Generali
  • Micaela Fredi
  • Ilaria Cavazzana
  • Franco Franceschini
  • Luca Cantarini
  • Minoru Satoh
  • Carlo SelmiEmail author
Brief Report

Abstract

This study aims to characterize myositis-specific antibodies in a well-defined cohort of patients with idiopathic inflammatory myopathy and to determine their association with cancer. Sera from 40 patients with polymyositis, dermatomyositis, and controls were tested by protein and RNA immunoprecipitation to detect autoantibodies, and immunoprecipitation-Western blot was used for anti-MJ/NXP-2, anti-MDA5, and anti-TIF1γ/α identification. Medical records were re-evaluated with specific focus on cancer. Anti-MJ/NXP-2 and anti-TIF1γ/α were the most common antibodies in dermatomyositis. In six dermatomyositis cases, we found five solid forms of cancer and one Hodgkin’s lymphoma in long-term remission. Among patients with cancer-associated dermatomyositis, three were positive for anti-TIF1γ/α, two for anti-Mi-2, and one for anti-MJ/NXP-2. The strongest positivity of anti-TIF1γ was seen in two active forms of cancer, and this antibody was either negative or positive at low titers in the absence of cancer or in the 7-year remission Hodgkin’s lymphoma. Four out of twenty (20 %) patients with polymyositis had solid cancer, but no specific association with autoantibodies was identified; further, none of the four cases of antisynthetase syndrome had a history of cancer. No serum myositis-associated autoantibody was observed in control sera, resulting in positive predictive value 75 %, negative predictive value 78.5 %, sensitivity 50 %, specificity 92 %, and area under the ROC curve 0.7083 for the risk of paraneoplastic DM in anti-TIF1γ/α (+) patients. Myositis-specific autoantibodies can be identified thanks to the use of immunoprecipitation, and their association with cancer is particularly clear for anti-TIF1γ/α in dermatomyositis. This association should be evaluated in a prospective study by immunoprecipitation in clinical practice.

Keywords

Biomarkers Cancer Idiopathic inflammatory myositis Immunoprecipitation 

Notes

Acknowledgments

This work was supported by the JSPS KAKENHI (Grants-in-Aid for Scientific Research) Grant Number 15K08790 for MS.

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Lundberg IE et al (2016) Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 280(1):39–51CrossRefPubMedGoogle Scholar
  2. 2.
    Ceribelli A. et al. (2016) The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review. Clin Rev Allergy ImmunolGoogle Scholar
  3. 3.
    Gunawardena H. (2015) The Clinical Features of Myositis-Associated Autoantibodies: a Review. Clin Rev Allergy ImmunolGoogle Scholar
  4. 4.
    Satoh M. et al. (2015) A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy ImmunolGoogle Scholar
  5. 5.
    Targoff IN (1992) Autoantibodies in polymyositis. Rheum Dis Clin N Am 18(2):455–482Google Scholar
  6. 6.
    Ceribelli A et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32(6):891–897PubMedGoogle Scholar
  7. 7.
    Satoh M et al (2012) Autoantibodies to transcription intermediary factor TIF1beta associated with dermatomyositis. Arthritis Res Ther 14(2):R79CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fiorentino DF et al (2016) PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjogren's syndrome. Ann Rheum Dis 75(6):1145–1151CrossRefPubMedGoogle Scholar
  9. 9.
    Ceribelli A et al (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37(10):2071–2075CrossRefPubMedGoogle Scholar
  10. 10.
    Ceribelli A et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14(2):R97CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yamasaki Y et al (2016) Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol 26(3):403–409CrossRefPubMedGoogle Scholar
  12. 12.
    Palaniappan P, Lionel AP, Kumar S (2014) Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate. J Clin Rheumatol 20(8):454–455CrossRefPubMedGoogle Scholar
  13. 13.
    Rider LG et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223–243CrossRefGoogle Scholar
  14. 14.
    Ichimura Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71(5):710–713CrossRefPubMedGoogle Scholar
  15. 15.
    Tiniakou, E. and A.L. Mammen, Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. Clin Rev Allergy Immunol, 2015.Google Scholar
  16. 16.
    Selva-O'Callaghan A et al (2010) Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 22(6):627–632CrossRefPubMedGoogle Scholar
  17. 17.
    Targoff IN et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689CrossRefPubMedGoogle Scholar
  18. 18.
    Gunawardena H et al (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47(3):324–328CrossRefGoogle Scholar
  19. 19.
    Kaji K et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46(1):25–28CrossRefGoogle Scholar
  20. 20.
    Chinoy H et al (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345–1349CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fujikawa K et al (2009) Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 38(4):263–267CrossRefPubMedGoogle Scholar
  22. 22.
    Selmi C et al (2016) Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev 15(2):162–166CrossRefPubMedGoogle Scholar
  23. 23.
    Cavazzana I et al (2016) Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1–5CrossRefPubMedGoogle Scholar
  24. 24.
    Chan EK et al (2016) Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 25(8):797–804CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2016

Authors and Affiliations

  • Angela Ceribelli
    • 1
  • Natasa Isailovic
    • 1
  • Maria De Santis
    • 1
  • Elena Generali
    • 1
  • Micaela Fredi
    • 2
  • Ilaria Cavazzana
    • 2
  • Franco Franceschini
    • 2
  • Luca Cantarini
    • 3
  • Minoru Satoh
    • 4
  • Carlo Selmi
    • 1
    • 5
    Email author
  1. 1.Division of Rheumatology and Clinical ImmunologyHumanitas Research HospitalMilanItaly
  2. 2.Unit of Rheumatology, Spedali CiviliBresciaItaly
  3. 3.Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and NeurosciencesUniversity of SienaSienaItaly
  4. 4.Department of Clinical NursingUniversity of Occupational and Environmental HealthKitakyushuJapan
  5. 5.BIOMETRA DepartmentUniversity of MilanMilanItaly

Personalised recommendations